Autophagy is a protective mechanism that renders cells viable in stressful conditions. Emerging evidence suggests that this cellular process is also a tumor suppressor pathway. Previous studies showed that cyclin-dependent kinase inhibitors (CDKIs) induce autophagy. Whether retinoblastoma protein (RB), a key tumor suppressor and downstream target of CDKIs, induces autophagy is not clear. Here we first demonstrate that RB triggers autophagy and that the RB activators p16INK4a and p27/kip1 induce autophagy in an RB-dependent manner. RB binding to E2F is required for autophagy induction and E2F1 antagonizes RB-induced autophagy, leading to apoptosis. Downregulation of E2F1 in cells results in high levels of autophagy. Our findnigs indicate that RB induces autophagy by repressing E2F1 activity. We speculate that this newly discovered aspect of RB function is relevant to cancer development and therapy.
Results

RB Induces Autophagic Responses in RB-Deficient Cells
To test our hypothesis that RB induces autophagy, we first transduced RB into the following RBdefective human cancer cells: sarcoma osteogenic (Saos-2) cells, hepatoma (Hep3B) cells, and brain tumor stem cells (MDNSC23) (15) . The exogenous RB protein induced autophagy in all three cell lines ( Fig. 1 and Supplementary Fig. S1 ). Specifically, we examined whether the transfer of RB induced the conversion of microtubule-associated protein light chain 3 (LC3)-I to LC3-II, a biochemical marker of autophagy that is correlated with the formation of autophagosomes. Immunoblotting analyses revealed an accumulation of LC3-II in the cells treated with RB, but not in the mock-treated or green fluorescent protein (GFP)-treated cells (Fig.   1A ). Consistently, RB also triggered the formation of autophagosomes/autolysosomes visualized by punctuate enhanced GFP (EGFP)-LC3 in Saos-2 cells that constitutively express the fusion protein (Fig. 1B) . In more than 80% of the RB-treated cells, EGFP-LC3 was not soluble and presented green fluorescent dots, whereas less than 20% of the control cells displayed the same pattern (Fig. 1B) . Ultimately, these data were confirmed by an ultrastructural study of the cells with a transmission electron microscope, which revealed accumulation of membrane-rimmed vacuoles with characteristics of autophagosomes/autolysosomes in Saos-2 ( We then challenged the autophagy mechanism by downmodulating Beclin 1, a key activator of the pathway. As expected, silencing Beclin 1 in Saos-2 cells with siRNA decreased the RB-mediated processing of the formation of autophagosomes/autolysosomes and membranebound LC3-II ( Fig. 1D and Supplementary Fig. S2 ). In agreement with these results was our observation that RB expression in Saos-2 cells, in a polymerase chain reaction (PCR)-based Fig. S3 ). Overall, our data indicate that RB restoration in RB-deficient cells triggers autophagy.
RB Promotes Autophagosome Formation and Maturation
The accumulation of autophagosomes and LC3-II in the cells could be due to either the increased formation or the decreased turnover of vesicles. To determine how RB affects the autophagy flux,
we took advantage of a double-tagged mRFP-EGFP-LC3 construct (ptfLC3) (21), which is detected as yellow fluorescent (green merged with red) in nonacidic structures (autophagosomes and amphisomes) and as red only in autolysosomes due to the quenching of EGFP in these acidic structures. As shown in Figure 2 , more than 70% RB-transduced cells displayed tremendous red fluorescence punctuation while only less than 10% mock or AdCMV-treated cells demonstrated this phenotype. However, when the cells were treated with Bafilomycin A1 (which inhibits the fusion of autophagosomes with lysosomes) to stop the turnover of autophagosomes, different from the cells transduced with RB, we found extraordinary amount of punctuate yellow fluorescence in the cytoplasm ( Fig. 2A) . These data indicate that RB increases the transport of mRFP-EGFP-LC3 to acidic lysosomes, i.e., formation of autolysosomes. Moreover, electron microscopic examination of the cells revealed that Bafilomycin A1 caused the accumulation of vacuoles in RB-expressing cells that filled most of the space in the cytoplasm, whereas the vacuoles in mock or GFP-expressing cells occupied less than half of the space in the cytoplasm ( Supplementary Fig. S4 ), indicating that RB stimulated a higher rate of autophagosome 
CDKIs Cause Autophagy in an RB-Dependent Manner
Since RB activity is positively regulated by CDKIs, such as p16 and p27/kip1 (p27), we asked whether activation of the RB pathway by CDKIs would result in autophagy in these cells. To this end, we transferred p16 to glioblastoma-astrocytoma (U-87 MG) and human osteosarcoma (U-2 OS) cell lines that express wild-type RB. The ectopic p16 protein triggered the lipidation of LC3, resulting in an increase of LC3-II in both cell lines (Fig. 3A) . Accordingly, more than 60% of the U-87-EGFP-LC3 cells showed a marked punctate pattern of green fluorescence after transduction of p16, whereas less than 20% of the control cells showed a similar pattern (Fig.   3B ). Moreover, when we transferred p16 to U-87-shRB cells, in which RB expression had been knocked down by shRNA against RB (Fig. 3C) , we observed that downmodulation of RB prevented the conversion of LC3-I to LC3-II, indicating that it rendered U-87 MG cells resistant to p16-mediated autophagy (Fig. 3C ).
In addition to p16, the best documented CDKI that is involved in the positive regulation of autophagy is p27 (11, 12). Unlike p16, p27 has other targets in addition to RB (27-29). When we transferred p27 to U-2 OS and Saos-2 cells, in a dose-dependent manner, U-2 OS cells were much more sensitive to p27, resulting in conversion of LC3-I to LC3-II that was not observed in Saos-2 cells (Fig. 3D ) and suggesting that RB might be one of the factors involved in p27-mediated autophagy.
Discussion
The RB/E2F1 pathway, crucial in regulating cell growth and apoptosis, is disrupted in virtually all human cancers (31). Here, we report that RB positively regulates autophagy by repressing E2F1 activity. Our results indicate that, instead of preventing autophagosome turnover in the cells, RB activity, or lack of E2F1 activity, promotes autophagy flux, from the formation of autophagosomes to their fusion with lysosomes. Our data reveal a previously unknown function of the RB/E2F1 pathway that might contribute to its role in cancer suppression and resistance to cancer therapy.
A balanced RB/E2F1 pathway is required to maintain cellular homeostasis. We found that excessive RB activity or lack of E2F1 causes autophagy and RB/E2F interaction is required for RB-mediated autophagy. Moreover, excessive E2F1 activity antagonizes RB-induced autophagy, leading to apoptosis. Therefore, in addition to the opposite roles of RB and E2F1 in regulating the cell cycle and apoptosis (30), our data suggest a model in which the interplay between RB and E2F1 also regulates autophagy (Fig. 7) . We speculate that adequate RB/E2F1 activity ensures a basal level of autophagy that is critical to maintaining normal cellular and molecular processes in the cell. Given the negative effects of autophagy on tumorigenesis (2), autophagy could be part of the mechanism through which RB acts as a tumor suppressor. In this regard, the involvement of PTEN, p53, and RB, the three most frequently mutated genes in human cancers, in regulating autophagy suggests a strong mechanistic link between stresssensing pathways, autophagy, and tumor suppression. Tumor suppressors, such as RB, may induce autophagy as a housekeeping mechanism to recycle damaged macromolecules and organelles to ensure the stability of the genome (32). In fact, it has been reported that basal levels of proteolysis or autophagic degradation in cancer cells was less than in their normal Aside from its housekeeping function, autophagy can also act as a protective mechanism to prolong cell survival under stressful conditions (38). In certain scenarios, autophagy constitutes a stress adaptation that suppresses apoptosis to avoid cell death (39). In addition to its central role in inhibiting cell proliferation, RB also plays a crucial role in inhibiting apoptosis (7) .
Studies in RB-mutant mouse show massive apoptosis in neurons (40). Interestingly, Atg7
deficiency in the central nervous system also causes massive neuronal loss in the cerebral and cerebellar cortices (41), suggesting a cross-talk between autophagy and apoptosis (39). Thus, on top of autophagy/apoptosis regulation by RB/E2F1 interplay (Fig. 7) , RB-mediated autophagy might inhibit apoptosis as well. Moreover, during its growth, the tumor is usually poorly vascularized in the center area, and in this environment, autophagy has a more prominent role in sustaining cell viability in cancer cells (42). Previous work has shown that most sporadic cancers inactivate RB by phosphorylation, rather than by mutations in the RB gene itself Overall, our study suggests that RB-induced autophagy provides a possible new mechanistic link between RB, cancer cell survival, and resistance to cancer therapy.
Although the role of RB in modulating autophagy seems to be well defined here, the role of E2F1 could be more complex. In fact, E2F1 has a dual role as a tumor suppressor and an oncogene and, as such, can positively regulate both cell proliferation and cell death (47). Thus, E2F1 may exert a contextual role in autophagy as well. A weak E2F1 transactivation of autophagy-related genes was observed in a drug-induced E2F1-expressing system (48). However, our data demonstrated that overactivated E2F1 blocked RB-induced autophagy and led to apoptosis (Fig. 5) . One of the possible molecular targets of E2F1 in the suppression of autophagy is Bcl-2, which blocks autophagy by binding Beclin 1 and prevents activation of the PI3Kc3 complex (25). Our previously published results revealed that Bcl-2 is a transcriptional target of E2F1 (26) and here we show that repression of E2F1 by RB therefore leads to downmodulation of Bcl-2 ( Supplementary Fig. S3 and Fig. 5 ), contributing to the triggering of autophagy. Although the mTOR pathway is a key negative regulator of autophagy (49). We examined the phosphorylation status of p70S6K, a substrate of mTOR (50). We did not observe any changes of the total p70S6K level and its phosphorylation level after introducing RB into Saos-2 and MDNSC23 cells or p16 into U-87 MG and U2 OS cells (data not shown). We assume that mTOR does not play a role under this circumstance. Thus RB-induced autophagy is more relevant to E2F1-mediated Bcl-2 expression than affecting mTOR pathway. However, it is now clear that E2F1 transactivates more than 2000 genes and that the role of E2F1 in regulating transcription is highly dependent on context (47). Therefore, it is overly simplistic to identify one or two players to completely explain the delicate balance between RB and E2F1 in the regulation of autophagy. Besides, further study will be required to determine whether RB/E2F1 modulation of autophagy is independent of its role in cell cycle regulation.
On the other hand, RB interacts with more than 200 proteins (6), one of which is the hypoxia-inducible factor, which is a potent inducer of autophagy under hypoxic conditions (51).
In these extreme circumstances, RB protein seems to negatively modulate hypoxia-inducible factor-induced autophagy by attenuating BNIP3 induction (52). However, in our system, transfer of RB to cancer cells under normoxia resulted in the up-regulation of BNIP3 ( Supplementary Fig.   S3 ), suggesting a marked difference between the regulation of autophagy under normoxic and hypoxic conditions.
In summary, our data unequivocally demonstrate that the RB/E2F1 pathway plays a role in regulating autophagy. Moreover, the existence of such a rheostat-like module to regulate the delicate balance between autophagy and apoptosis ( Fig. 7) provides a new interpretation for the role of RB in tumor suppression during development, cell survival under stressful conditions, and cancer cell resistance to therapy. 
